Mike Evers of Orthoworld estimates that orthopedic sales grew in the mid-single digits for the first quarter of 2022 and that the remaining challenges are manageable.

Content republished with permission from ORTHOWORLD® Inc.

Mike Evers of Orthoworld discusses how the orthopedic market finds itself in familiar territory in early 2022, with COVID infections surging to record levels. While we await fourth-quarter and full-year results from orthopedic companies, we'll summarize below our expectations and questions for the market as it enters the third year of disruption from the pandemic.

Content republished with permission from ORTHOWORLD® Inc.

Mike Evers of Orthoworld discusses how the orthopedic market outperformed expectations in the first half of 2021, given gaps in vaccine coverage and the surging delta variant.

Content republished with permission from ORTHOWORLD® Inc.

Mike Evers of Orthoworld discusses the state of Orthopedic markets and M&A in 2Q21. As we near 2Q earnings, we're watching for a barometer of the market's recovery, momentum in M&A, as well as the evolution toward digital.

Content republished with permission from ORTHOWORLD® Inc.

Carolyn LaWell of Orthoworld offers this advice regarding medical device commercialization in emerging markets: consider new geographies early in your worldwide expansion based on ease of regulatory and reimbursement processes.

Content republished with permission from ORTHOWORLD® Inc.

Early earnings previews from companies reinforce Orthoworld’s belief that the orthopedic market will decline around -10% in 2020. Below they preview some positives from the fourth quarter and the most recent COVID and U.S. jobs data, as well as some early thoughts for 2021.

Content republished with permission from ORTHOWORLD® Inc.